Advanced search
Publication Cover
Acta Oncologica Volume 50, 2011 - Issue 3
Journal homepage
1,327
Views
39
CrossRef citations to date
0
Altmetric
Research Article

Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma

Simon Ekman Section of Oncology, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, SwedenCorrespondence[email protected]
,
Jan-Erik Frödin Department of Oncology, Karolinska University Hospital, Solna, Stockholm, Sweden
,
Johan Harmenberg Axelar AB, Karolinska Institutet, Science Park, Stockholm, Sweden
,
Antonina Bergman Section of Radiology, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
,
Åsa Hedlund Section of Oncology, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
,
Pia Dahg Section of Oncology, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
,
Carina Alvfors Uppsala Clinical Research Center, Uppsala, Sweden
,
Birgitta Ståhl Axelar AB, Karolinska Institutet, Science Park, Stockholm, Sweden
,
Stefan Bergström Section of Oncology, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
&
Michael Bergqvist Section of Oncology, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
 show all
Pages 441-447 | Received 23 Feb 2010, Accepted 03 Jun 2010, Published online: 11 Aug 2010

Citations (39)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Michael Bergqvist, Georg Holgersson, Igor Bondarenko, Elena Grechanaya, Alexey Maximovich, György Andor, Maria Klockare, Marcus Thureson, Markus Jerling & Johan Harmenberg. (2017) Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer. Acta Oncologica 56:3, pages 441-447.
Read now
Simon Ekman, Johan Harmenberg, Jan-Erik Frödin, Stefan Bergström, Cecilia Wassberg, Staffan Eksborg, Olle Larsson, Magnus Axelson, Markus Jerling, Lars Abrahmsen, Åsa Hedlund, Carina Alvfors, Birgitta Ståhl & Michael Bergqvist. (2016) A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial. Acta Oncologica 55:2, pages 140-148.
Read now
Helena Jernberg-Wiklund & Kenneth Nilsson. (2012) Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma. Upsala Journal of Medical Sciences 117:2, pages 166-177.
Read now
Vivek Subbiah, Laura S Angelo & Razelle Kurzrock. (2011) Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver – Will it hit the moving target?. Expert Opinion on Investigational Drugs 20:11, pages 1471-1477.
Read now
Elizabeth Buck & Mark Mulvihill. (2011) Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opinion on Investigational Drugs 20:5, pages 605-621.
Read now

Articles from other publishers (34)

Xiaoli Li, Guoli Wang, Xiaolin Zhou, Huijie Zhao, Xiaojie Chen, Qixiao Cui, Minjing Li, Xihang Gao, Xiaoyu Wei, Lei Ye, Defang Li & Pan Hong. (2023) Targeting HSP90 with picropodophyllin suppresses gastric cancer tumorigenesis by disrupting the association of HSP90 and AKT . Phytotherapy Research 37:10, pages 4740-4754.
Crossref
Qiang Li, Yuan Li, Hui Yuan, Fujun Yang, Yan Huang, Xiao Song & Lei Jiang. (2022) PET morphology helps distinguish solitary and solid pulmonary tuberculosis from non-small cell lung cancer. Japanese Journal of Radiology.
Crossref
Xiongye Xu, Yanli Qiu, Simin Chen, Shuaishuai Wang, Ruifu Yang, Baomo Liu, Yufei Li, Jiating Deng, Yan Su, Ziying Lin, Jincui Gu, Shaoli Li, Lixia Huang & Yanbin Zhou. (2022) Different Roles of the Insulin-like Growth Factor (IGF) Axis in Non-small Cell Lung Cancer. Current Pharmaceutical Design 28:25, pages 2052-2064.
Crossref
Mohini Singh, Ashish Dahal, Magali de Sauvage, Juliana Larson & Priscilla K. Brastianos. 2022. Neurological Complications of Systemic Cancer and Antineoplastic Therapy. Neurological Complications of Systemic Cancer and Antineoplastic Therapy 55 78 .
Anhao Tian, Bo Kang, Baizhou Li, Biying Qiu, Wenhong Jiang, Fangjie Shao, Qingqing Gao, Rui Liu, Chengwei Cai, Rui Jing, Wei Wang, Pengxiang Chen, Qinghui Liang, Lili Bao, Jianghong Man, Yan Wang, Yu Shi, Jin Li, Minmin Yang, Lisha Wang, Jianmin Zhang, Simon Hippenmeyer, Junming Zhu, Xiuwu Bian, Ying‐Jie Wang & Chong Liu. (2020) Oncogenic State and Cell Identity Combinatorially Dictate the Susceptibility of Cells within Glioma Development Hierarchy to IGF1R Targeting. Advanced Science 7:21, pages 2001724.
Crossref
Olaf Beck, Claudia Paret, Alexandra Russo, Jürgen Burhenne, Margaux Fresnais, Kevin Steimel, Larissa Seidmann, Daniel-Christoph Wagner, Nadine Vewinger, Nadine Lehmann, Maximilian Sprang, Nora Backes, Lea Roth, Marie Astrid Neu, Arthur Wingerter, Nicole Henninger, Khalifa El Malki, Henrike Otto, Francesca Alt, Alexander Desuki, Thomas Kindler & Joerg Faber. (2020) Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma. Cancers 12:4, pages 793.
Crossref
Alexandra Russo, Claudia Paret, Francesca Alt, Jürgen Burhenne, Margaux Fresnais, Wolfgang Wagner, Martin Glaser, Hannah Bender, Sabrina Huprich, Patrick N. Harter, Katharina Filipski, Nadine Lehmann, Nora Backes, Lea Roth, Larissa Seidmann, Clemens Sommer, Marc A. Brockmann, Torsten Pietsch, Marie A. Neu, Arthur Wingerter & Jörg Faber. (2019) Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. International Journal of Molecular Sciences 20:17, pages 4267.
Crossref
Vanessa Benham, Blair Bullard, Thomas S. Dexheimer, Matthew P. Bernard, Richard R. Neubig, Karen T. Liby & Jamie J. Bernard. (2019) Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay. Scientific Reports 9:1.
Crossref
Maciej Tarnowski, Marta Tkacz, Katarzyna Zgutka, Joanna Bujak, Patrycja Kopytko & Andrzej Pawlik. (2017) Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo. BMC Cancer 17:1.
Crossref
Houssein Abdul Sater. (2017) Receptor Tyrosine Kinases in Human Platelets: A Review of Expression, Function and Inhibition in Relation to the Risk of Bleeding or Thrombocytopenia from Phase I through Phase III Trials. Journal of Cancer Prevention & Current Research 8:6.
Crossref
Roudy Chiminch Ekyalongo & Douglas Yee. (2017) Revisiting the IGF-1R as a breast cancer target. npj Precision Oncology 1:1.
Crossref
Anastassios Philippou, Panagiotis F. Christopoulos & Dr. Michael Koutsilieris. (2017) Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer. Mutation Research/Reviews in Mutation Research 772, pages 105-122.
Crossref
Yingying Sun, Xilin Sun & Baozhong Shen. (2017) Molecular Imaging of IGF-1R in Cancer. Molecular Imaging 16, pages 153601211773664.
Crossref
Natalie J. Serkova & S. Gail Eckhardt. (2016) Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents. Frontiers in Oncology 6.
Crossref
Tatiana V. Denisenko, Irina V. Sorokina, Vladimir Gogvadze & Boris Zhivotovsky. (2016) Mitotic catastrophe and cancer drug resistance: A link that must to be broken. Drug Resistance Updates 24, pages 1-12.
Crossref
Young Wha Koh, Dok Hyun Yoon, Cheolwon Suh, Hee Jeong Cha & Jooryung Huh. (2015) Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression. International Journal of Experimental Pathology 96:4, pages 232-239.
Crossref
Thomas Strömberg, Xiaoying Feng, Maryam Delforoush, Mattias Berglund, Yingbo Lin, Magnus Axelson, Olle Larsson, Patrik Georgii-Hemming, Johan Lennartsson & Gunilla Enblad. (2015) Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells. Medical Oncology 32:7.
Crossref
Qi Zhang, Jing Pan, Ronald A. Lubet, Yian Wang & Ming You. (2015) Targeting the insulin-like growth factor-1 receptor by picropodophyllin for lung cancer chemoprevention. Molecular Carcinogenesis 54:S1, pages E129-E137.
Crossref
Elena Gershtein & Nikolay Kushlinskii. (2015) Clinical prospects of IGF-signaling system components study in ovarian cancer patients. Drug Metabolism and Personalized Therapy 30:2, pages 75-85.
Crossref
Laura W. Bowers, Emily L. Rossi, Ciara H. O’Flanagan, Linda A. deGraffenried & Stephen D. Hursting. (2015) The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link. Frontiers in Endocrinology 6.
Crossref
Steven L. Wood, Maria Pernemalm, Philip A. Crosbie & Anthony D. Whetton. (2015) Molecular histology of lung cancer: From targets to treatments. Cancer Treatment Reviews 41:4, pages 361-375.
Crossref
Georg Holgersson, Stefan Bergström, Johan Harmenberg, Magnus Ringbom, Maria Klockare, Markus Jerling, Simon Ekman, Kristina Lamberg Lundström, Hirsh Koyi, Eva Brandén, Olle Larsson & Michael Bergqvist. (2015) A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. Medical Oncology 32:4.
Crossref
Helen King, Tamara Aleksic, Paul Haluska & Valentine M. Macaulay. (2014) Can we unlock the potential of IGF-1R inhibition in cancer therapy?. Cancer Treatment Reviews 40:9, pages 1096-1105.
Crossref
Leonard Girnita, Claire Worrall, Shin-Ichiro Takahashi, Stefan Seregard & Ada Girnita. (2013) Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cellular and Molecular Life Sciences 71:13, pages 2403-2427.
Crossref
Mark S. Butler, Avril A. B. Robertson & Matthew A. Cooper. (2014) Natural product and natural product derived drugs in clinical trials. Nat. Prod. Rep. 31:11, pages 1612-1661.
Crossref
Pushpendra Singh, Jimi Marin Alex & Felix Bast. (2013) Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Medical Oncology 31:1.
Crossref
Xuping Wu, Linda Sooman, Malin Wickström, Mårten Fryknäs, Christine Dyrager, Johan Lennartsson & Joachim Gullbo. (2013) Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro . Molecular Cancer Therapeutics 12:8, pages 1526-1536.
Crossref
Ran Rostoker, Keren Bitton-Worms, Avishay Caspi, Zila Shen-Orr & Derek LeRoith. (2013) Investigating New Therapeutic Strategies Targeting Hyperinsulinemia's Mitogenic Effects in a Female Mouse Breast Cancer Model. Endocrinology 154:5, pages 1701-1710.
Crossref
Renato Baserga. (2012) The decline and fall of the IGF‐I receptor. Journal of Cellular Physiology 228:4, pages 675-679.
Crossref
Lina Reslan & Charles Dumontet. 2013. Resistance to Immunotherapeutic Antibodies in Cancer. Resistance to Immunotherapeutic Antibodies in Cancer 1 24 .
Anuradha Soundararajan, Jinu Abraham, Laura D. Nelon, Suresh I. Prajapati, Lee Ann Zarzabal, Joel E. Michalek, Stanton F. McHardy, Douglas S. Hawkins, Suman Malempati & Charles Keller. (2012) 18F-FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models. Pediatric Blood & Cancer 59:3, pages 485-492.
Crossref
Seung Hyun Oh, Ju-Hee Kang, Jong Kyu Woo, Ok-Hee Lee, Edward S. Kim & Ho-Young Lee. (2012) A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer. International Journal of Cancer 131:3, pages 537-547.
Crossref
Giorgio V. Scagliotti & Silvia Novello. (2012) The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treatment Reviews 38:4, pages 292-302.
Crossref
XIAOYING FENG, EIMAN ALEEM, YINGBO LIN, MAGNUS AXELSON, OLLE LARSSON & THOMAS STRÖMBERG. (2012) Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: Clinical implications. International Journal of Oncology 40:4, pages 1251-1258.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.